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Abstract
Background: Leukemia is distinguished by abnormal proliferation of leukocytes. Although there has been some
progress in developing novel cancer therapies, no significant improvement was observed in the overall survival rate
over the last decade. Selective cyclooxygenase-2 (COX-2) inhibitors are known to inhibit tumor growth by exerting
antimetastatic and antiangiogenic effects through inhibition of COX –dependent and independent pathways. The
ability of two new triaryl-oxadiazole derivatives, compounds A (3-(4-chlorophenyl) -5-(4-flurophenyl)-4-Phenyl-4,5-
dihydro-1,2,4-oxadiazole) and B (3,5-bis(4-chlorophenyl)-4-Phenyl-4,5-dihydro-1,2,4-oxadiazole), to induce apoptosis
in human erythroleukemia K562 cells was evaluated and the upstream mechanism was investigated.
Methods: K562 cells were treated with compounds A and B at their IC50 concentrations and analyzed by DAPI
staining and Annexin-V-FLUOS labelling solution. Nuclear factor kappa-B (NF-κB) activation was evaluated by
TransAM kit. Cyclooxygenase-2 (COX-2), Caspase-3, Bax, Bcl-2, ferritin heavy chain (FHC), extra cellular signal-regulated
kinase (ERK), p-ERK and early growth response protein-1 (Egr1) levels were determined using Western blotting, while
c-Myc mRNA level was investigated by RT-PCR.
Results: Changes in nuclear morphology and the increased annexin-V/PI staining revealed the apoptotic cell death in
compounds A- and B-treated K562 cells. A significant reduction in NF-κB activity as well as FHC and p-ERK levels were
detected in these cells. No change was observed in the levels of Bax, Bcl-2, Caspase-3, COX-2, c-Myc and Egr1,
following treatment with the two compounds. Collectively, compounds A and B potentiate apoptosis as shown by
DAPI staining, flowcytometry, FHC and p-ERK downregulation and NF-κB inactivation.
Conclusion: Two compounds induce apoptosis in a COX-2-independent manner which also appears to be
independent from mitochondria, caspase and c-Myc/Egr1 pathways.
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Background
Leukemia, a cancer of the body’s blood-forming tissues,
including the bone marrow and the lymphatic system, is
distinguished by abnormal proliferation of leukocytes.
Based on the International Classification of Childhood
Cancer, leukemia represents one of the largest diagnostic
groups among individuals under 15 years of age with inci-
dence of 34 % [1]. Although there has been some progress
in developing novel cancer therapies, no significant im-
provement was observed in the overall survival rate over
the last decade [2]. Nonsteroidal anti-inflammatory drugs
(NSAIDs) with their pain relief and anti-inflammation
properties have also been the focus of attention as anti-
cancer agents [3]. The targets of traditional NSAIDs are
cyclooxygenases 1 and 2 (COX-1 and COX-2), enzymes
involved in the production of prostaglandins from ara-
chidonic acid [4]. In this regard, NSAIDs are known to
inhibit tumor growth by exerting antimetastatic and
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antiangiogenic effects through inhibition of COX activity,
however, a COX-independent pathway has also been sug-
gested [3, 5].
In addition to common NSAIDs, the newly developed
selective COX-2 inhibitor, celecoxib, with a better gas-
trointestinal risk profile, has been considered as a cost-
effective alternative [6]. Celecoxib has been proven as a
potent candidate for treating cancer, with several on-
going clinical trials as well as in various animal tumor
models [5, 7]. Celecoxib has also been demonstrated to
have inhibitory effect on the growth of K562 cells, and
induce apoptosis [5, 8].
Celecoxib represents a 1, 2-di-aryl heterocyclic struc-
ture and used as an ideal lead compound for developing
novel derivatives with potent apoptosis-inducing activity
[9, 10]. We have recently reported that two compounds
with triaryl-oxadiazole structures known as compounds
A (3- (4-chlorophenyl) -5-(4-flurophenyl)-4-Phenyl-4,5-
dihydro-1,2,4-oxadiazole) and B (3,5-bis(4- chlorophe-
nyl)-4-Phenyl-4,5-dihydro-1,2,4-oxadiazole) (Fig. 1) show
significant biological features such as antiproliferative
activity with considerable IC50 values (21.66 and 22.23 μM)
in human erythroleukemia (K562) cell line after a 24 h
treatment [11]. In the present investigation, we examined
the mechanism leading to apoptosis during treatment of
K562 cell line with the two new celecoxib derivatives, com-
pounds A and B.
Methods
Drugs and reagents
Compounds A and B were synthesized by the Depart-
ment of Medicinal Chemistry, Tehran University of
Medical Science (Tehran, Iran). Dulbecco’s Modified
Eagle’s Medium (DMEM) and fetal bovine serum (FBS)
were purchased from Gibco-BRL (Rockville, IN, USA).
Annexin-V-FLUOS kit was prepared from Roche Applied
Science (Indianapolis, USA). Polyclonal anti–caspase-3
(1:500), anti-Bcl-2 (1:500), anti-Bax (1:500), anti-COX-2
(1:1000), anti-GAPDH (1:1000) antibodies and mono-
clonal anti-ERK (1:1000), anti-Phospho-ERK (1:1000),
anti-FHC (1:100) and anti-Egr-1 (1:200) antibodies were
purchased from Abcam (Cambridge MA, USA). Anti-
rabbit IgG horseradish peroxidase (HRP) antibody (1:5000)
was obtained from Cell Signaling Technology (Beverly,
MA, USA). All other chemicals were in high purity and
prepared from Merck (Darmstadt, Germany).
Cell culture
K562 cells were obtained from the cell bank of Pasture
Institute of Iran (NCBI). Cells were cultured in DMEM
medium containing 10 % FBS, 100 U/mL penicillin and
100 μg/mL streptomycin. These cells were incubated at
37 °C and 5 % CO2 in a humidified atmosphere and
then were treated with compounds A and B at the IC50
concentrations (21.66 and 22.23 μM) for 8 and 16 h.
Analysis of cell morphology by DAPI staining
The treated and untreated cells were stained by DAPI 4’,6-
diamido-2-phenylindole hydro chloride) (Roche Applied
Science, Indianapolis, USA), and their morphology was
observed under a Zeiss fluorescence microscope (Zeiss,
Germany). Photomicrographs were taken with an Olym-
pus digital camera (Tokyo, Japan).
Identification of apoptosis by Annexin-V/PI staining
Following treatment, 106 cells were washed in PBS and re-
suspended in 100 μL of annexin-V-FLUOS labeling solu-
tion containing 2 μL annexin-V-FLUOS labeling agent,
2 μL Propidium Iodide (PI) solution and 1 mL incubation
buffer to achieve a concentration of 106 cells/mL. Follow-
ing incubation at 37 °C for 15 minutes, cells were analyzed
by flowcytometry. Annexin-V binds to cells expressing
phosphatidyl serine on the outer layer of the cell mem-
brane, and PI stains the cellular DNA of those with a com-
promised cell membrane [12]. This allows for the
discrimination of live cells (unstained with either fluoro-
chrome or PI) from apoptotic (stained with annexin-V)
and necrotic cells (stained with PI).
Western blotting
K562 cells were treated with compounds A and B at
their IC50 concentrations for 16 h. Proteins were extrac-
ted from distinctively treated cells, collected and lysed in
lysis buffer (Tris 62.5 mM (pH 6.8), DTT 50 mM, SDS
Fig. 1 Structure of the two new celecoxib derivatives
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10 %, glycerol) in the presence of protease inhibitors.
Then, equal amounts of protein were heated to 95 °C,
separated in 12 % SDS-polyacrylamide gels and trans-
ferred to PVDF membranes. The membrane was then
blocked for 2 h in TBST (50 mmol/L Tris-Cl, pH 7.6,
150 mmol/L NaCl and 0.1 % Tween 20) containing 1 %
(w/v) casein, and then incubated with primary antibodies
overnight, followed by incubation with HRP conjugated
goat anti-rabbit IgG for 2 h. Blots were then developed
using ECL advance western blotting detection kit. The
signals from each protein band were normalized against
the GAPDH (Glyceraldehyde Phosphate Dehydrogenase)
content using the polyclonal anti-GAPDH antibody. The
expression level of control was designated value “1”, and
thereby the expression ratios of the treatments were
expressed in relation to the control.
ELISA-based TransAM assay
K562 cells were treated with compounds A and B at
their IC50 concentrations for 16 h. Proteins of treated
cells were extracted. The experiments were performed
according to manufacturer’s instructions for the ELISA-
based TransAM p65 kit (TransAM NF-κB p65 Transcrip-
tionFactor Assay kit). Briefly, 20 μg of protein extract per
well was added to a 96-well plate coated with the immo-
bilized oligonucleotide containing the NF-κB consensus
sequence (5’-GGGACTTTCC-3’) and incubated for 1 h
at room temperature with mild agitation. p65 protein
present in the extract will specifically bind to this se-
quence. Next, anti-p65 antibody (100 μL, at a 1:1000
dilution) was added to each well and incubated for
1 h, followed by the addition of 100 μL of horseradish per-
oxidase (HRP)-conjugated antibody (1:1000 dilution) for
yet another 1 h. After adding 100 μL of the developing so-
lution for up to 5 min, colorimetric reaction was stopped
and ELISA reader was used to quantify the difference be-
tween the intensity of NF-κB p65 by reading absorbance
at 450 nm with a correction wavelength of 630 nm.
Semiquantitative RT-PCR
For analysis of c-Myc mRNA expression levels, cells
were treated or not treated with compounds A and B for
16 hours, and total RNA was extracted with RNX-Plus
(CinnaGen, Iran) following the manufacturer’s protocol.
1 μg of total RNA was used to perform reverse transcrip-
tion with the RevertAid first strand cDNA synthesis Kit
(Thermo, Lithuania) following the manufacturer’s proto-
col. The resulting reverse transcription products were
stored at −70 °C until use.
Reaction products were quantified by RT-PCR using a
2X TaqPreMix (Master Mix) PCR Kit (CinnaGen, Iran)
according to the manufacturer’s instructions. PCR of
GAPDH that was chosen as an internal control was car-
ried out in the same tubes as for the genes. The PCR
primers of GAPDH and c-myc were synthesized according
to the references [13, 14]. Sequences of the primers were
as follows: c-myc (Forward: 5’- TGGTGCTCCATGAGGA
GACA-3’; Reverse: 5’-GTGTTTCAACTGTTCTCGTC-
3’), GAPDH (Forward: 5’-GAGCCCGCAGCCTCCCGCT
T-3’; Reverse: 5’- CCCGCGGCCATCACGCCACAG-3’).
Statistical analysis
Each experiment was performed at least three times and
representative data were shown. Data in the graph are
given as mean values ± standard error (SE) of the mean.
Significant differences among groups were determined
using a one-way ANOVA followed by the posttest tukey.
Results
Apoptosis induction in K562 cells following compounds A
and B treatments
In order to examine whether compounds A and B ex-
hibit cytotoxicity in K562 cells through apoptosis, DAPI
staining analysis was undertaken in order to observe
morphological changes in K562 cells following treatment
with compounds A(21.66 μM) and B(22.23 μM) for 8
and 16 h (Fig. 2). Morphological evidence of apoptosis
was detected as chromatin condensation and nuclear
fragmentation following 8 h (Fig. 2d) and to a greater ex-
tent at 16 h (Fig. 2h) treatment with compound B,
whereas compound A-treated K562 cells showed slight
morphological changes at 8 h (Fig. 2c) and to a greater
extent at 16 h (Fig. 2g).
Apoptosis induced by compounds A and B in K562
cells was confirmed by staining cells with Annexin-V/PI
and subjecting them to flowcytometry. In the dual par-
ameter fluorescent dot plots, the number of cells in early
(annexin V+/PI−, the lower right quadrant) and late
(annexin V+/PI+, the upper right quadrant) apoptosis
were counted (Fig. 3). As shown in Table 1, 95.02 % of
untreated cells were viable. However, treatment with
compounds A (IC50) and B (IC50) for 16 h resulted in a
reduction in the number of viable cells to 90.48 % and
85.95 %, respectively, whereas, the percentage of annexin
V+/PI− cells (early apoptosis) increased significantly.
These results demonstrate that compounds A and B
show antitumor activities in K562 cells, mainly through
the induction of apoptotic cell death.
Effect of compounds A and B on Bax, Bcl-2 and caspase-3
levels
In order to determine the possible involvement of the
caspase cascade in the execution phase of apoptosis,
caspase-3 level was investigated following treatment of
cells with the IC50 concentration of compounds A and B
by Western blot analysis. As shown in Fig. 4a, treatment
with either compound had no effect on the cleavage of
caspase-3 in K562 cell line after 8 and 16 h. In addition,
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the expression of Bcl-2 and Bax, measured by Western
blot analysis, revealed no apparent change in Bax/Bcl-2
ratio at 8 and 16 h (Fig. 4b and c).
Effect of compounds A and B on COX-2 levels
In order to determine the possible involvement of the
COX-2 pathway in apoptosis induced by compounds A
and B, COX-2 level was investigated following treatment
of cells with the IC50 concentrations of the two com-
pounds. As shown in Fig. 5a and b, neither of the com-
pounds had any significant effect on the expression of
COX-2 following a 16 h treatment of K562 cells.
Effect of compounds A and B on NF-ĸB activity
As NF-ĸB plays a critical role in the apoptosis process
[15], the effects of compounds A and B on NF-ĸB p65
activity was assessed. As shown in Fig. 6, following a
16 h treatment of cells with compounds A and B(IC50),
a significant (p < 0.05) reduction in the concentration of
nuclear p65 subunit was observed.
Effect of compounds A and B on FHC, p-ERK, c-Myc and
Egr1 levels
To reveal upstream mechanism of apoptosis induction
following treatment with celecoxib derivatives, levels of
certain factors, located downstream of NF-ĸB in the
Fig. 2 Apoptotic morphological changes in K562 cells. a K562 control cells after 8 h. b K562 cells treated with DMSO for 8 h. c K562 cells treated
with compound A at 21.66 μM for 8 h. d K562 cells treated with compound B at 22.23 μM for 8 h. e K562 control cells after 16 h. f K562 cells
treated with DMSO for 16 h. g K562 cells treated with compound A at 21.66 μM for 16 h. h K562 cells treated with compound B at 22.23 μM for
16 h. Cells were stained with DAPI and observed by fluorescent microscopy
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apoptosis signaling pathway, including FHC, p-ERK, c-
Myc and Egr1 were determined through Western and
RT- PCR analysis (Fig. 5 and 7).
Administration of compounds A and B to K562
cells resulted in a reduction in FHC protein level,
which was significant (p < 0.01) following 16 h of
treatment (Fig. 5a and c). Treatment of cells with the
two compounds A and B also revealed a significant
(p < 0.01 and p < 0.001, respectively) reduction in the
levels of p-ERK which coincided with a lack of
change in those of ERK after 16 h of treatment
(Fig. 5a, d and e). Collectively, these results demon-
strate that treatment with compounds A and B lead
to a reduction in both ERK phosphorylation and FHC
levels. Finally, Semi-quantitative RT-PCR analysis re-
vealed no change in c-Myc mRNA levels in cells
treated with compounds A or B (IC50) after 16 h
(Fig. 7). Furthermore, consistent with the transcript
levels of c-Myc, protein levels of Egr1 were not altered
by compounds A and B after 16 h (Fig. 5a and f).
Discussion
To study the cytotoxicity of compounds A and B, as two
new triaryl-oxadiazole derivatives which well fitted to
COX-2 active site [11], their effects on the induction of
“programmed cell death” in K562 cells, and the mecha-
nisms by which these compounds induce apoptosis were
investigated. K562 cells are a human cancer blood cell
line derived from the chronic myeloid leukemia (CML)
tumor lineage, which has been considered as a good
model to study the cancer inhibitory effects of celecoxib
derivatives [5, 8]. Celecoxib, as a first generation of
COX-2 inhibitors, has gained a great deal of attention in
cancer studies. Although, the cardiotoxic effect has been
established in long period treatment of patients with cel-
ecoxib, and for this reason, its application in chemopre-
vention has been restrained [16]. In this regard, the two
new compounds A and B show significant antiprolifera-
tive activity with considerable IC50 values (21.66 and
22.23 μM) in K562 cell line after a 24 h treatment [11].
The main mechanism that attributes to the observed
effects of COX-2 inhibitors against different types of
cancer is apoptosis [17]. Apoptosis is a kind of cell death
known as “programmed cell death” that occurs in differ-
ent physiological and pathological situations and marked
by typical morphological and biochemical features, in-
cluding cell shrinkage, nuclear DNA fragmentation and
membrane blebbing [18]. Following treatment of K562
cells with compounds A and B for 16 h, the fluorescence
microscopic observations demonstrated typical morpho-
logical changes indicating cell damage; however, these
changes were not as much following 8 h of incubation
(Fig. 2). The data obtained from annexin-V/PI analysis
were in agreement with the morphological changes
showing that compounds A and B induce apoptosis after
16 h (Table 1).
The two major apoptotic pathways known to operate
in mammalian cells include the receptor (extrinsic) and
the mitochondrial (intrinsic) pathways. Through the
intrinsic pathway, members of the Bcl-2 protein family
operate as regulators of survival and death during apop-
tosis induction [19, 20]. Although the role of
Fig. 3 Flowcytometry analysis to quantify apoptosis in K562 cells. a Untreated control K562 cells. b Cells treated with compound A (21.66 μM). c
Cells treated with compound B (22.23 μM). Cells were stained with annexin V and propidiumiodide. The results shown are representative of three
independent experiments. Quadrant 3, living cells An−/PI−; Quadrant 4, early apoptotic cells An+/PI−; Quadrant 2, late apoptotic cells An+/PI+;
Quadrant 1, necrotic cells An−/PI+
Table 1 Percentage of K562 cells in each state after treatment with compounds A (21.6 μM) and B (22.23 μM) for 16 h
Compound Vital cells (%) An–/PI– Early apoptosis (%) An+/PI– Late apoptosis (%) An+/PI+ Necrosis (%) An–/PI+
A 90.48±0.38 0.427497 0.61±0.09 4.9±0.23
B 85.91±0.62 9.82±0.58 1.05±0.02 3.22±0.08
Control 95.02±1.1 1.28±0.06 0.36±0.05 3.34±0.4
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Fig. 5 Effect of compounds A (21.6 μM) and B (22.23 μM) on COX-2, FHC, ERK1/2, p-ERK1/2 and Egr1 expression in K562cells after incubation for
16 hours. a Immunoblot showing the expression levels of COX-2, FHC, ERK1/2, p-ERK1/2, Egr1 and GAPDH. b Ratios of COX-2/control. c Ratios of FHC/
control. d Ratios of ERK/control. e Ratios of p-ERK/control. f Ratios of Egr1/control. The results of 3 independent experiments are presented as mean ±
standard error (*P < 0.05, **P < 0.01 vs. the solvent group)
Fig. 4 Expression analysis of apoptosis associated proteins by Western blot analysis. K562 cells were treated with compounds A (21.66 μM) and B
(22.23 μM). a Immunoblot showing the expression levels of caspase-3, Bcl-2, Bax and GADPH. b Ratios of Bax/Bcl-2 after 8 h. c Ratios of Bax/Bcl-2
after 16 h. The results of 3 independent experiments are presented as mean ± standard error
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mitochondria in compounds A- and B-induced apop-
tosis is not clear in K562 cells, several cytotoxic drugs as
well as COX-2 inhibitors are known to initiate apoptosis
through the mitochondrial pathway [21]. Our data clearly
demonstrate that Bax and Bcl-2 do not have a critical role
in the induction of apoptosis in K562 cells (Fig. 4), sug-
gesting a mitochondria-independent apoptotic pathway
induced by compounds A and B. The role of caspase-3 in
the mitochondria-independent apoptotic pathway has also
been well understood [22]. However, apparently com-
pounds A and B induce apoptosis in a caspase- independ-
ent mechanism as caspase-3 levels were not altered by
compounds A and B in K562 cells (Fig. 4a). Collectively
these data demonstrate that compounds A and B induce
apoptosis through both a mitochondria- and caspase- in-
dependent mechanism in K562 human leukemia cells.
Our obtained data are in agreement with the recent report
indicating the execution of apoptosis without the involve-
ment of caspases. Indeed, apoptosis induced in these cells
by compounds A and B has been shown to involve the
activation of proteases other than caspases [23].
The antiproliferative and apoptotic effects of celecoxib
in K562 cells are associated with COX-2 inhibition [5].
However, it is well established that tumor growth inhib-
ition by selective COX-2 inhibitors might as well be me-
diated through COX-2-independent mechanisms [24]. In
this study, treatment with compounds A and B were
found to cause no change in COX-2 levels (Fig. 5).
These findings demonstrate that the apoptotic effects of
these compounds in K562 cells are mediated by a COX-
2 independent pathway. Interestingly, it was recently
reported that celecoxib derivatives with no COX-2 in-
hibitory action can be considered as anti-cancer agents
without increasing the cardiovascular risk [25]. Therefore,
the two compounds may have a potential in being used as
chemotherapeutic agents with little or no cardiovascular
side effects.
Induction of apoptosis can be triggered by a number
of stimuli, activating a cell suicide program that is con-
stitutively present in most vertebrate cells. In diverse cell
types, Rel/NF-kappaB transcription factors are involved
in regulation of apoptosis by either inducing or perhaps
more commonly blocking it [26]. NF-κB regulates the ex-
pression of more than 400 genes involved in inflamma-
tion, cell survival, proliferation, invasion and angiogenesis.
NF-κB also affects apoptosis during tumor development
and progression [27], often leading to apoptosis resistance
[28]. On the other hand, a reduction in NF-κB mitogenic
signaling has been associated with the anticancer effects
of celecoxib treatment on mouse mammary epithelial
tumor cells mediated through a COX-2 independent path-
way [24]. Our data also demonstrate that treatment of
K562 cells with compounds A and B results in a reduction
of NF-κB expression (Fig. 6) in a COX-2-independent
manner.
The primary iron storage factor, FHC (Ferritin heavy
chain), which mediates the antioxidant and protective
activities of NF-κB, is induced downstream of NF-κB
and required for TNFα-induced apoptosis [29]. Rezaie
Fig. 7 Effect of compounds A (21.6 μM) and B (22.23 μM) on c-Myc mRNA levels in K562 cells after incubation for 16 hours. a Immunoblat showing
the expression level of c-Myc. b Ratios of c-Myc/control. The results of 3 independent experiments are presented as mean ± standard error
Fig. 6 Effect of compounds A (21.6 μM; IC50) and B (22.23 μM; IC50)
on NF-κB activation in K562 cells after incubation for 16 hours. The
results of 3 independent experiments are presented as mean ± standard
error (*P < 0.05, vs. the solvent group)
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et al. (2011) reported FHC down-regulation in J774.A1
macrophage-like cell lines, following celecoxib treatment
[30]. Our study confirms down-regulation of FHC ex-
pression induced by compounds A and B in K562 cell
line (Fig. 5). Interestingly, our data exhibit the down
regulation of both NF-κB and FHC which may not be
surprising as NF-κB, as a transcription factor, has been
involved in the regulation of FHC expression.
Moreover, mitogen-activated protein kinase (MAPK)/
extracellular signal-regulated protein kinase (ERK) have
been implied in transmitting the apoptotic signal [14].
MAPK family members are mediators of signal trans-
duction pathways [22]. Importantly, NF-ĸB acts the up-
stream of MAPKs in the signaling of certain anticancer
drugs [31]. The ERK pathway, a major player in the
regulation of cell growth, survival, and differentiation, is
induced in response to mitogens and growth factors
[22], however, evidence for ERK pathway mediating
apoptosis has also been reported [32]. According to pre-
vious studies, celecoxib has different roles in ERK1/2
activation in different cells. The present study revealed
growth inhibition of K562 cells following compounds A-
and B- treatment via down regulation of p-ERK1/2
(Fig. 5). These data indicate that the mechanism of anti-
proliferative activities of the designed compounds may
be mediated through NF-ĸB and ERK inhibition.
Anticancer drugs induce apoptosis through different
intracellular targets and cause DNA damage [21]. An-
other factor contributing to the regulation of apoptosis
includes the early gene, c-Myc [33]. There has been con-
flicting reports on the regulation of c-Myc expression dur-
ing NSAID-induced apoptosis. NSAID-induced apoptosis
of gastric cancer cells may be mediated through the up-
regulation of c-Myc proto-oncogene [34], while NS-398, a
COX-2 inhibitor, reduces c-Myc expression in rat colon
cancer cells [35]. In the present study, RT-PCR analysis
revealed no alteration in the levels of c-Myc transcript in
K562 cells treated with compounds A or B compared to
the control (Fig. 7b), however, compounds A and B in-
duced apoptosis in K562 cells, suggesting the operation of
a c-Myc independent apoptotic pathway. Our results are
consistent with those of Ostrowski et al. (2003) who
demonstrated a lack of alteration in basal and serum-
stimulated c-Myc expression following treatment of rat
hepatoma HTC-IR cells with aspirin or celecoxib. In
addition, when treated with the selective COX-2 inhibitor,
NS-398, no change was observed in c-Myc mRNA
levels in rat colon mucosa as compared to untreated
animals [36].
Previous studies also showed that c-Myc directly in-
duces transcription of a noncanonical target gene, Egr1
(Early growth response-1) [37]. Egr1 can suppress the
growth of a number of tumor cells, including leukemia.
A diverse of anticancer agents, such as COX inhibitors,
act through the modulation of Egr1 [38]. In a pancreatic
cancer model, tolfenamic acid-induced Egr1 expression
appears to have an essential role in the activation of
apoptosis [39]. Our data revealed no change in the levels
of Egr1 in K562 cell line treated with compounds A and
B (Fig. 5). Therefore, the apoptosis in K562 cell line
induced by compounds A and B appears to be inde-
pendent from the c-myc/Egr1 pathway. These results are
in line with our previous report showing an apoptosis
induced by compounds A and B via a c-myc/Egr1 inde-
pendent pathways in breast cancer cell line with a differ-
ent mechanism [40].
Conclusion
In summary, the present study reveals that compounds A
and B, as two new triaryl-oxadiazole derivatives with
COX-2 inhibitory structures, induce apoptosis in K562
cells through a mitochondrial-, caspase- and COX-2-
independent pathways. This COX-2-independent mech-
anism involves a reduction in NF-κB levels and a subse-
quent reduction in the downstream FHC and P-ERK1/2
signaling. Our findings also demonstrate a more pro-
nounced apoptotic effect in response to compound B than
compound A in K562 cells. Future studies need to be di-
rected towards identifying the downstream mediators in
order to reveal a more clear and detailed molecular path-
way that would help in the development of compounds A
and B as suitable chemotherapeutic agents against
leukemia.
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